Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Clonal Cytopenias of Uncertain Significance (CCUS)
NCT06788691Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in clonal cytopenia of undetermined significance (CCUS), sponsored by Weill Cornell Medicine. Primary endpoint: Number of patients achieving cytopenia responses as defined by HI-E, HI-P, HI-N, mHI-E responses at 24 weeks. Started Mar 2025; status: recruiting.
02
Drugs
luspatercept
03
Conditions
clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT06788691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788691.